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Abstract 36 
Idiopathic pulmonary fibrosis (IPF) is characterised by accumulation of extra cellular matrix (ECM) 37 
proteins and fibroblast proliferation. ECM cross-linking enzymes have been implicated in fibrotic 38 
diseases and we hypothesised that the ECM in IPF is abnormally cross-linked which enhances 39 
fibroblast growth and resistance to normal ECM turnover. We used a combination of in vitro ECM 40 
preparations and in vivo assays to examine the expression of cross-linking enzymes and the effect of 41 
their inhibitors on fibroblast growth and ECM turnover. Lysyl oxidase like 1, 2, 3 and 4 were expressed 42 
equally in control and IPF derived fibroblasts. Transglutaminase 2 was more strongly expressed in IPF 43 
fibroblasts. Lysyl oxidase like 2, transglutaminase 2 and transglutaminase generated cross-links were 44 
strongly expressed in IPF lung tissue. Fibroblasts grown on IPF ECM had higher LOXL3 protein 45 
expression and transglutaminase activity compared with those grown on control ECM. IPF derived 46 
ECM also enhanced fibroblast adhesion and proliferation compared with control ECM. Inhibition of 47 
lysyl oxidase and transglutaminse activity during ECM formation affected ECM structure as visualised 48 
by electron microscopy and reduced the enhanced fibroblast adhesion and proliferation of IPF ECM 49 
to control levels. Inhibition of transglutaminase, but not lysyl oxidase activity, enhanced the turnover 50 
of ECM in vitro. In bleomycin treated mice, during the post-inflammatory fibrotic phase, inhibition of 51 
transglutaminases was associated with a reduction in whole lung collagen. Our findings suggest that 52 
the ECM in IPF may enhance pathological cross-linking which contributes to increased fibroblast 53 
growth, resistance to normal ECM turnover to drive lung fibrosis.    54 
Introduction 55 
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia with an 56 
incidence of 7.44 per 100 000 person-years and a prevalence which is rising year on year1. The lung 57 
architecture is progressively remodelled by the proliferation of fibroblasts, myofibroblasts and the 58 
deposition of extracellular matrix (ECM) leading to respiratory failure with a median survival of less 59 
than three years2.  60 
 61 
The deposition of fibrosis in IPF is heterogenous both in its spatial distribution and evolution over time. 62 
Regions of densely packed fibroblasts / myofibroblasts and ECM proteins, particularly collagen I, 63 
termed fibroblast foci, tend to be situated adjacent to less involved regions of the lung3. The activated 64 
myofibroblast is thought to be the main source of pathological ECM in IPF and presentdeposited both 65 
in the fibroblast foci and the less densely involved areas of the lung4.  The mammalian ECM consists of 66 
around 300 individual proteins which include the classical ECM proteins collagens, fibronectin, elastin, 67 
proteoglycans and glycoproteins, but also a large number of signaling molecules, post-translational 68 
modifying enzymes and proteases. The ECM is a dynamic and versatile part of the cellular environment 69 
influencing almost all cell functions, including proliferation and migration by binding to growth factors, 70 
by acting as a co-receptor for various ligands and signaling via endogenous growth factor domains or 71 
matricryptins generated by proteolytic processing5 6. Additionally, changes in the biomechanical 72 
properties of the ECM can induce gene expression programs affecting cell differentiation and 73 
function7. Consistent with its importance, multiple levels of regulation ensure tight control of ECM 74 
production, degradation, and remodeling8. However, in fibrotic diseases and cancers, abnormal ECM 75 
dynamics and organisation are major drivers of abnormal cell behaviour and ultimately organ failure9.  76 
 77 
In addition to ECM proteins, matrix degrading proteases, including matrix metalloproteinases (MMPs) -78 
1 and -7, a disintegrin-like and metalloprotease with thrombospondin type 1 motif (ADAMTS)-14 and 79 
ADAMTS-5 are strongly overexpressed in IPF10 suggesting the accumulation of ECM in IPF may not be 80 
due to suppression of MMP activity as previously thought11. A potential explanation for the increase in 81 
both ECM proteins and proteases is that the ECM in IPF may be abnormally resistant to ECM degrading 82 
proteases. Stabilisation of the ECM by cross linking of collagen/fibronectin by transglutaminase 2 (TG2)12 83 
and collagen/elastin by lysyl oxidase like 2 (LOXL2)13 respectively, can protect ECM from proteolysis in 84 
other organs14,15.  85 
 86 
TG2 is an 80 kDa protein with a number of enzymatic and non-enzymatic functions. TG2 cross-links the 87 
ECM by calcium dependent transamidation / deamidation of the glutamine or lysine side chains of many 88 
proteins resulting in lysine crosslink formation. LOXL2 is a member of the lysyl oxidase gene family, which 89 
share conserved C-terminal copper binding and catalytic domains, and act as extracellular copper-90 
dependent amine oxidases that deaminate the lysine ε-amino group to cross-linkage collagen and elastin 91 
monomers16. Both TG2 and LOXL2 are overexpressed in IPF and their inhibition or absence during the 92 
induction of fibrosis reduces lung inflammation and fibrosis in bleomycin treated animals12,13. Here, we 93 
will test the hypothesis hypotheses that the ECM in IPF is aberrantly cross-linked, supports fibroblast 94 
growth, and confers resistance against ECM turnover by proteolysis and that inhibition of ECM cross-95 
linking can affect these processes.  96 
Methods 97 
Full details of all methods and supporting data are provided in the online supplement.  98 
 99 
Cells, tissues and serum samples 100 
IPF derived fibroblasts were obtained from patients undergoing lung biopsy for the diagnosis of 101 
interstitial lung disease. Control fibroblasts were obtained from patients undergoing lung tumor 102 
resections from uninvolved areas of the specimen. Cells were cultured in DMEM containing 10% foetal 103 
bovine serum and characterised by immuno-staining for α-SMA, S100A4 and fibroblast activation 104 
protein (supplementary figure 1). IPF and control lung tissue was obtained from The Nottingham Health 105 
Science Biobank. IPF and control serum with linked clinical data were obtained from the Trent Lung 106 
Fibrosis study which has been described previously17. The use of cells, tissues and serum was approved 107 
by the Nottingham Research Ethics committee and all patients provided written informed consent. 108 
 109 
ECM preparations and assays 110 
ECM was obtained from three IPF derived and three control fibroblast cultures as described18. ECM 111 
protein was analysed in two fractions, that soluble in RIPA buffer (soluble fraction) and that isolated by 112 
physical scraping and solubilsation in an 8M urea based buffer (insoluble fraction). ECM structure was 113 
visualized by electron microscopy using a Jeol 6060LV scanning electron microscope (Jeol ltd. UK). For 114 
ECM degradation assays, fibroblasts were incubated with 1µC/ml tritiated proline during matrix 115 
deposition. Tritiated proline labelled ECM preparations were digested with recombinant MMPs -1, -2 116 
and -7 (R&D Systems, UK) and tritium measured in the soluble fraction by scintillation counting and 117 
expressed as disintegrations per minute (DPM) as a marker of ECM proteolysis. The effect of ECM 118 
stiffness on TG2 activity was analysed by culturing control fibroblasts on tissue culture platessubstrates 119 
of variable stiffness (SoftSubstrates, CA, USA). In vitro TG2 cross-linking was performed by incubation of 120 
recombinant human TG2 protein (500 ng/ml) or controls with 50ug/ml collagen type 1 (Advanced 121 
Biomatrix, USA) and 50ug/ml fibronectin (Sigma Aldrich, UK) overnight at 37 ᵒc on a rotating shaker. 122 
 123 
In vitro cell proliferation, adhesion and apoptosis assays 124 
Fibroblasts were cultured on ECM preparations for 48 hours and cell growth/proliferation determined 125 
by MTT reduction assay, and 5-ethynyl-2′-deoxyuridine (EdU) DNA incorporation and cell counting as 126 
described19. For adhesion assays, fluorescently labelled control fibroblasts were seeded onto ECM 127 
preparations and adherent cells measured by average well fluorescence after two hours. Apoptosis was 128 
assessed using an In Situ Cell Death Detection kit, AP (Roche Diagnostics, UK). 129 
 130 
Cross-linking enzyme analysis 131 
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Gene expression for LOX, LOXL1, 2, 3, 4 and TG2 in IPF derived and control fibroblasts grown on IPF and 132 
control matrix were measured by real time RT-PCR using β-actin as the reference gene as described in 133 
the supplement. TG2 and LOXL3 protein were measured by ELISA (CusaBio Biotech Co. Ltd, MD, USA and 134 
Cloud Clone Corp., TX, USA.). Transglutaminase activity was determined using the Transglutaminase 135 
Assay Kit (Sigma Aldrich) and LOX activity by a Fluorometric Lysyl Oxidase Activity Assay Kit (Abcam, 136 
Cambridge UK). Immunohistochemistry was performed as described 20. 137 
 138 
Bleomycin model of fibrosis 139 
Six to eight week old C57BL/6 mice received 60 IU of intra-tracheal bleomycin as described 21. At either 140 
14, 24 or 34 days later, intraperitoneal cystamine (100mg/kg) was administered daily for ten days. 141 
Mice were then sacrificed by terminal anesthesia, blood samples taken, the lungs excised and snap 142 
frozen. Total lung collagen was assessed by hydroxyproline assay as described22. Animal work was 143 
approved by the Animal Welfare and Ethical Review Board of the University of Nottingham. Full details 144 
are provided in the on-line supplement. 145 
  146 
Results 147 
Expression of ECM cross-linking enzymes in fibroblasts, lung tissue and serum 148 
We examined the expression of the LOX and transglutaminase family enzymes in control and IPF derived 149 
fibroblasts cultured on tissue culture plastic by quantitative, real time RT-PCR. LOXL1-4 mRNAs were 150 
detected in all cells with expression not significantly different between control and IPF derived 151 
fibroblasts. The LOX transcript was also present in all cells but at very low levels. The TG2 transcript 152 
(TGM2) was expressed in normal fibroblasts and over 70 fold more strongly in IPF derived fibroblasts; 153 
(control 2.90 vs. IPF 177.5. n=3, P<0.05). Transglutaminase 6 and 7 transcripts were not present in either 154 
cell type (Figure 1). Total ECM protein, total collagen, collagen synthesis (supplementary figure 2) and 155 
collagen isoform gene expression did not vary between IPF and control fibroblast ECM (supplementary 156 
figure 3). 157 
 158 
We then examined cross-linking enzymes, N-epsilon γ-glutamyl lysine cross-links, α-smooth muscle 159 
actin, collagen, using picro-sirius red and the proliferation marker ki67 in lung tissue from three control 160 
and eight patients with IPF. TG2 and N-epsilon γ-glutamyl lysine cross-links are present in control alveolar 161 
epithelium and strongly expressed in all areas of IPF tissue. Immunostaining for TG2, and the TG2 cross-162 
link was ubiquitous in all areas of IPF tissue, including those with dense fibrosis, regions less involved by 163 
fibrosis and fibroblast foci. TG2 and its associated cross-link paralleled the deposition of collagen and 164 
αSMA in lung tissue. PIn general proliferating cells identified by ki67 positivity were also present in all 165 
areas of IPF tissue (figure 2). Within areas of dense fibrosis and fibroblast foci, proliferating cells tended 166 
to have fibroblast morphology whereas in areas of lesser fibrosis, had a morphology consistent with 167 
inflammatory cells.  LOXL3 was not expressed in normal lung tissue. LOXL2 was also expressed in control 168 
and IPF tissue. LOXL3 was not expressed in normal lung tissue and was present at low levelThere was 169 
weak staining for LOXL3 in IPF tissue although positive control tissue (small intestine, not shown) stained 170 
more strongly (supplementary figure 4).  171 
 172 
To determine the systemic expression of these cross-linking enzymes in patients with IPF we studied 173 
levels of circulating LOXL3 and TG2 in 60 patients with IPF, 30 of whom had died within a year of 174 
recruitment, 30 who had survived for more than one year and 30 age and sex matched controls. There 175 
were no significant differences, for either LOXL3 or TG2, between those with IPF and age matched 176 
controls. For all 60 with IPF, there was no association between serum LOXL3 or TG2 and FVC. Similarly, 177 
there was no difference between serum LOXL3 or TG2 levels between patients who were alive or who 178 
had died (supplementary figure 75). 179 
 180 
IPF matrix induces LOXL3 and TG2 expression 181 
We hypothesized that ECM derived from IPF fibroblasts may promote its own cross linking. To test this 182 
we produced ECM from fibroblasts derived from three control and three patients with IPF. All six cell 183 
types were seeded onto each matrix type and cross linking gene expression examined by quantitative, 184 
real time RT-PCR. LOXL3 was strongly induced in both cell types when grown on IPF derived ECM with 185 
the matrix type accounting for 75.5% of total variation (P<0.001. Figure 3a). TG2 mRNA showed a trend 186 
towards increased expression in IPF derived fibroblasts over control cells independent of matrix 187 
substrate, however this was not significant. Other cross-linking enzymes did not vary with cell or ECM 188 
type.  189 
 190 
TGransglutaminase activity and LOXL3 protein were measured in supernatants from these cultures. TG2 191 
Transglutaminase activity in supernatants increased in a cell dependent manner. in IPF fibroblasts on 192 
control matrix showedhad increased TG2 activity over control derived cells on control matrix (control 193 
0.22AU vs. IPF 0.36AU. n=3, P<0.05). In addition, , whereas TG2 activity increased by 2 fold when control 194 
fibroblasts were seeded onto IPF ECM when compared with control matrix (control 0.22AU vs. IPF 195 
0.42AU. n=3, P<0.01. Figure 3b and supplementary figure 5). Consistent with the gene expression data, 196 
LOXL3 protein expression was up regulated 3.3 fold in control fibroblasts grown on IPF compared with 197 
control matrix (control 280.4pg/ml vs. IPF 922.9pg/ml. n=3, P<0.001) and 4.2 fold in IPF fibroblasts grown 198 
on IPF compared with control matrix (control 248.9pg/ml vs. IPF 1053pg/ml, n=3, P<0.001. Figure 3c). 199 
To determine if the observed changes were due to enhanced ECM stiffness we examined the 200 
transglutaminase activity of fibroblasts grown on substrates with a Young’s modulus varying between 201 
0.5-64 kPa and found that ECM stiffness had no effect on transglutaminase activity (Supplementary 202 
figure 86). 203 
 204 
IPF matrix enhances fibroblast adhesion and proliferation 205 
To determine whether IPF derived ECM contributes to an environment which supports expansion of the 206 
fibroblast population we examined adhesion, proliferation and resistance to apoptosis of fibroblasts on 207 
control and IPF derived ECM. IPF derived ECM enhanced control and IPF derived fibroblast adhesion by 208 
2.4 (P<0.05) and 7.5 fold (P<0.01) respectively over control ECM (Figure 4a). In the absence of a mitogen, 209 
MTT reduction and DNA synthesis did not differ when cultured on IPF and control derived ECM for 48 210 
hours. Stimulating growth with either 1% foetal bovine serum or PDGF-bb (5ng/ml) enhanced control 211 
fibroblast growthand metabolic activityMTT reduction on IPF derived ECM by 26 (P<0.0001) and 17 212 
(P<0.01) fold respectively (Figure 4b) . Furthermore, IPF ECM enhanced and DNA synthesis, as measured 213 
by EdU incorporation by xx1.22.4  in the presence of either FBS or PDGF-bb (P<0.01) &and xx2.11.2 fold 214 
(P<0.05) respectively (Figure 4b). In the absence of a mitogen, fibroblast number did not differ when 215 
staurosporine or fFas ligand as judged by DNA fragmentation, caspase 3 or parp PARP cleavage 216 
(supplementary figure 67). 217 
 218 
Enhanced adhesion and proliferation on IPF derived ECM is dependent on matrix cross-linking 219 
We then examined if the functional effects of IPF derived ECM were a consequence of ECM cross-linking. 220 
ECM preparations were produced by cells treated with inhibitors of TG2 (cystamine dihydrochloride) 221 
and the LOX family (beta amino-proprionitrile, βAPN). Treatment of cells with these inhibitors had no 222 
effect on the amount of ECM deposition nor cell viability (data not shown). To determine whether 223 
cystamine and βAPN affected ECM structure; we examined the ECM deposited by both cell types and 224 
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the effect of the cross-link inhibitors using scanning electron microscopy. Both cystamine and βAPN 225 
disrupted the ordered ECM fibrillary structure (figure 5a). The enhanced fibroblast adhesion on IPF 226 
derived ECM was reduced to a similar level to that of control ECM by both cystamine (vehicle = 334.0 227 
AU vs. cystamine = 283.2 AU, P < 0.0001, n=3) and βAPN (vehicle = 334.0 AU vs. βAPN =254.2 AU, 228 
P<0.0001, n=3. Figure 5b). Enhanced fibroblast proliferation was reduced 6.5 fold by cystamine 229 
treatment of IPF ECM (vehicle = 0.478 AU vs. cystamine = 0.073 AU, P < 0.01, n=3). Cystamine treatment 230 
of control ECM resulted in a paradoxical increase in MTT reduction in control cells but not control derived 231 
ECM. βAPN inhibited proliferation on IPF ECM in a similar manner to cystamine by 3.4 fold (vehicle = 232 
0.478 AU vs. βAPN = 0.139 AU, P<0.05, n=3. Figure 5c). 233 
 234 
To ensure these observations were not due to a non-specific effect of cystamine, we first examined LOX 235 
activity in cystamine treated cells and found no effect of cystamine on LOX cross-linking activity (data 236 
not shown). We next performed fibroblast adhesion and proliferation assays on in vitro cross-linked 237 
collagen / fibronectin coated plates which had been incubated with either vehicle control, recombinant 238 
TG2 (500 ng/ml) or TG2 and cystamine. Adhesion of MRC5 fibroblasts to this ECM coating was enhanced 239 
2.1 fold (P≤<0.05) by TG2 treatment. Co-incubation with cystamine completely abrogated the increased 240 
adhesion (figure 5d). Cell number in response to 1% serum over 72 hours was enhanced 1.4 fold (P ≤< 241 
0.05) by TG2 treatment and the increase blocked by cystamine (figure 5e). 242 
 243 
We then examined the co-localisation of the TG2 associated cross-link and proliferating cells identified 244 
by ki67 staining, in eight IPF lung samples. Both the cross-link and ki67 positive cells were ubiquitous 245 
within all regions ofin the IPF lung. In regions of less dense fibrosis, the proliferating cell morphology was 246 
macrophages. Mature fibrotic regions and fibroblast foci contained more densely packed structural cells 247 
and extracellular matrix where the ki67 positive cells were  likely to be myofibroblasts. Within the 248 
fibrotic regions, tand there was no simple association between the cross-linking and proliferation at the 249 
point examined (supplementary figure 89). 250 
 251 
Transglutaminase inhibition enhances matrix proteolysis 252 
We next asked if abnormal matrix cross-linking conferred resistance to proteolysis. ECM preparations 253 
were generated incorporating tritiated proline and the release of tritium into supernatants taken as a 254 
measure of matrix proteolysis. In all ECM preparations a low level of spontaneous ECM turnover was 255 
observed. Treatment of IPF fibroblasts during ECM deposition with the TG2 inhibitor cystamine 256 
increased spontaneous ECM turnover (vehicle 202 DPM vs. cystamine 549 DPM, P<0.01, n=3). To 257 
determine if the observed spontaneous ECM turnover was due to ECM resident proteases we treated 258 
the formed ECM preparations with a broad spectrum protease inhibitor which tended to reduce 259 
spontaneous ECM turnover. Addition of active MMP-1 had no further effect on ECM turnover in either 260 
control or cystamine treated IPF ECM preparations (figure 6). Direct activation of resident MMPs by the 261 
addition of APMA enhanced the turnover of IPF ECM formed in the presence of cystamine from all IPF 262 
derived cells however the effect varied between cells and did not achieve significance. Addition of 263 
activated MMP-1, -2 or -7 had no additional effect over the APMA vehicle. Cystamine had no effect on 264 
control ECM turnover and the LOX family inhibitor βAPN had no effect on proteolysis of either control 265 
or IPF derived ECM (supplementary figure 109). 266 
 267 
In vivo inhibition of TG2  268 
To determine if inhibition of transglutaminases in vivo would result in increased ECM turnover and a net 269 
reduction in fibrosis we examined the effect of cystamine in the mouse bleomycin model of fibrosis. In 270 
preliminary experiments we confirmed that bleomycin treatment of lung tissue resulted in increased 271 
transglutaminase activity. Ex vivo incubation of murine lung tissue with bleomycin resulted in a 2.2 fold 272 
increase in transglutaminase activity (P<0.001, n=3) which was almost completely abrogated by 273 
cystamine (P<0.05, n=3. Figure 7A). Following this we performed a time course and determined that the 274 
level of fibrosis no longer increased 24 days after bleomycin administration (supplementary figure 110). 275 
In the mouse model, cystamine administration from 24 to 34 days post bleomycin exposure was 276 
associated with a 24% reduction in total lung hydroxyproline (vehicle 1593µg vs. cystamine = 1198µg, 277 
P<0.05, n=3) but had no effect hydroxyproline in saline treated animals (figure 7b). 278 
Discussion 279 
Here we have shown that IPF derived ECM is strongly crosslinked and supports increased fibroblast 280 
adhesion and proliferation. Moreover, disruption of ECM cross-linking in vitro affects ECM structure 281 
and reduces enhanced fibroblast adhesion and proliferation, and inhibition of transglutaminases in 282 
vivo enhances ECM turnover. Further, expression of TG2 and the LOXL family in IPF are both ECM and 283 
cell dependent.  Collectively, these findings suggest that IPF ECM is abnormally cross-linked and this 284 
cross-linking is one factor which supports fibrosis by enhanced fibroblast growth and resistance to 285 
normal ECM turnover. 286 
 287 
The induction of the ECM cross-linking enzymes TG2 and LOXL3 by IPF ECM is consistent with the 288 
observations of Parker and colleagues who demonstrated that fibrotic ECM induces multiple pro-289 
fibrotic gene expression programs23. Collectively, these observations are consistent with fibrotic 290 
changes creating an environment that sustains further fibrosis and tissue remodelling. A number of 291 
potential mechanisms could explain the enhanced fibroblast adhesion and proliferation on fibrotic 292 
ECM. The increased activity of TG2 in IPF derived fibroblasts results in an increase in n-ε-γ-glutamyl 293 
lysine cross links between collagen and fibronectin. The alterations in ECM structure as a consequence 294 
of increased cross-linking may result in increased access to ECM pro-adhesive and proliferative signals 295 
and reduced adhesion and proliferation caused by inhibition of both TG2 and the LOXL family would be 296 
consistent with this. The relative larger increase in meatabolicmetabolic activity (MTT reduction) 297 
compared with the more modest increase in DNA synthesis may also suggest that IPF matrix also has 298 
effects upon fibroblast metabolism. In addition, transglutaminase activity enhances fibronectin 299 
deposition and changes in ECM proteins may affect adhesion and proliferation12. Enhanced cross 300 
linking may also alter ECM stiffness which is a driver of cell growth, survival and gene transcription 301 
however any such effect seems independent of TG2 activity which was unaffected by ECM stiffness in 302 
our study. It is also possible that the cross links themselves are capable of outside-in signaling to 303 
fibroblasts enhancing adhesion and proliferation. 304 
 305 
Whilst IPF derived cells have higher transglutaminase activity on control ECM, IPF derived ECM induces 306 
transglutaminase activity in control fibroblasts. Our data therefore suggest that both the cell and ECM 307 
origin determine transglutaminase activity. It is possible the effect of IPF ECM may lead to permanent 308 
changes in gene expression. The study by Parker and colleagues suggested that although the ECM was 309 
the primary driver of fibrotic gene expression by modulation of the pro-fibrotic micro-RNA miR-29, the 310 
cell type contributed synergistically to fibrotic gene expression24. Recent genetic studies suggest that IPF 311 
fibroblasts may have both genetic25 and potentially acquired epigenetic differences26 which may account 312 
for differences in gene expression.  313 
 314 
The TG2 generated n-ε-γ-glutamyl lysine cross link is resistant to proteolysis by MMP-1 and -2 in vitro 315 
and reduced cross-linking is likely to explain the increase in ECM turnover induced by the TG2 inhibitor27. 316 
Interestingly, we observed that that the TG2 inhibitor cystamine enhanced constitutive or spontaneous 317 
ECM turnover which was inhibited by a broad spectrum protease inhibitor and enhanced by APMA, an 318 
activator of MMPs. ECM proteolysis was not further enhanced by endogenous MMP-1, -2 or -7; 319 
proteases overexpressed in the lungs of those with IPF. Our findings are consistent with the presence of 320 
MMPs in the ECM preparation causing constitutive ECM turnover. Proteomic analysis of the ECM 321 
confirms the presence of multiple collagenolytic MMPs which could be activated by APMA and also 322 
ADAMS, serine proteases and cathepsins28. 323 
  324 
In vivo, intra-tracheal administration of bleomycin results in a strong inflammatory reaction leading to 325 
collagen deposition resolving over 14 to 21 days followed by the persistence of excess collagen in the 326 
absence of inflammation29. TG2 is a multi-functional protein with intra and extra-cellular, enzymatic and 327 
non-enzymatic actions in inflammation, cell death and survival30. In TG2 knockout animals, Bleomycin 328 
bleomycin induced lung fibrosis is reduced during the inflammatory and fibrotic phases of the bleomycin 329 
We have used a TG2 inhibitor during the established fibrotic phase of the model and observed a small 330 
reduction in total lung collagen at a point where the fibrosis had become established. We suspect that 331 
in addition to the anti-inflammatory effect on the generation of fibrosis observed by Olsen and 332 
colleagues, the effect on lung collagen seen in this model was likely to have been by the reduction in 333 
fibrosis driven transglutaminase cross linking allowing protease mediated ECM turnover. The 334 
combination of interruption of the proposed TGF-β/TG2 pro-fibrotic feedback loop, reduction of 335 
fibroblast growth and restoration of normal ECM turnover may all contribute to reduce the progression 336 
of fibrosis3112. Taken together our data suggest that inhibition of TG2 in fibrosis may reduce the burden 337 
fibrosis by multiple mechanisms. Recently, inhibition of the cross linking enzyme LOXL2 using a 338 
monoclonal antibody proved unsuccessful as a therapy for IPF31. The multiple cross-linking enzymes 339 
present in fibrotic lung tissue are likely to fulfil different functions and inhibition of TG2 remains a 340 
potential target in human lung fibrosis.  341 
 342 
In conclusion, we have found that inhibition of TG2 mediated cross-link formation reduces fibroblast 343 
adhesion, proliferation and enhances the turnover of ECM produced by IPF fibroblasts. These findings 344 
suggest that inhibition of transglutaminase cross-linking may be a potential therapy for IPF.   345 
Figure legends 346 
 347 
Figure 1. Expression of cross-linking enzyme transcripts in control and IPF derived fibroblasts. 348 
Quantitative gene expression of cross linking enzymes in three control and three IPF derived 349 
fibroblasts determined by real time PCR. Lysyl oxidase (LOX) was expressed at a very low level. Lysyl 350 
Oxidase like protein transcripts (LOXL) 1-4 were robustly expressed in control and IPF derived 351 
fibroblasts with LOXL3 showing a non-significant trend toward increased expression. 352 
Transglutaminase 2 mRNA (TG2) was expressed at a significantly higher level in the IPF derived 353 
fibroblasts. TG6 and TG7 were not detected. α-smooth muscle actin (ACTA2) is used as positive 354 
control. ***P<0.001 Data analysed with multiple unpaired t-test’s corrected for multiple comparisons 355 
using the Holm-Sidak method. Data presented ±SD, n=3. 356 
 357 
Figure 2. ECM cross-linking enzymes and transglutaminase mediated cross-links are expressed in IPF 358 
tissue. Immunohistochemical staining showing representative images of control lung and three areas 359 
of IPF lung tissue, densely fibrotic, less fibrotic and a fibroblast focus. Sequential sections are stained 360 
with haematoxylin and eosin (H+E), picrosirius red to identify collagens, and antibodies against α-361 
smooth muscle actin (αSMA), transglutaminase 2 (TG2), the TG2 generated n-ε γ-glutamyl lysine cross-362 
link and the proliferation marker ki67 (proliferating cells denoted by arrows).  Blue indicates 363 
haematoxylin counterstaining of nuclei. Isotype control sections are provided for immuno-stains of 364 
IPF tissue.  Magnification x420. 365 
 366 
Figure 3. IPF derived ECM induces LOXL3 protein and transglutaminase activity. (a) Three control and 367 
three IPF derived fibroblasts were cultured on three control and three IPF derived ECM preparations 368 
and gene expression for cross linking enzymes quantified by real time PCR. Transglutaminase 2 (TG2) 369 
mRNA was tended to be more strongly expressed in IPF fibroblasts irrespective of matrix substrate 370 
although this was not significant. LOXL3 was strongly induced on IPF derived ECM in both cell types. 371 
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LOX was weakly expressed on control ECM and further supressed on IPF derived ECM. (b) TG2 cross-372 
linking activity measured in three control and IPF fibroblasts is higher in IPF than control cells. IPF 373 
derived matrix enhances TG2 in control but not IPF derived fibroblasts. *P <0.05 (c) LOXL3 protein is 374 
strongly induced on IPF derived ECM. ***P <0.0001 (two way repeated measures ANOVA). 375 
 376 
Figure 4. IPF derived ECM enhances fibroblast adhesion and adhesion, cellular metabolismMTT 377 
reduction and DNA synthesisgrowth. Adhesion of three control and three IPF derived fibroblasts was 378 
quantified on tissue culture plastic (none) and three control and IPF derived ECM preparations and 379 
repeated three times. Both matrices significantly enhanced adhesion of normal fibroblasts. IPF matrix 380 
significantly enhanced adhesion of both fibroblast types over control matrix. (b) IPF ECM 381 
enhancesincreased proliferation metabolic activityMTT reduction and DNA synthesis of in cells in the 382 
presence oftreated with 1% foetal bovine serum (FBS) and platelet derived growth factor-bb (PDGF-383 
bb) for 48 hours  as assessed by MTT reduction(. **P<0.05, **P<0.01 and, ****P<0.001), (multiple t-384 
tests with Holm-Sidak correction) (two way repeated measures ANOVA)and also enhanced DNA 385 
synthesis as assessed by EdU incorporation under the same conditions (P<0.01 & P<0.05 respectively). 386 
 387 
Figure 5. Inhibition of cross linking reduces fibroblast adhesion and growth. (a) Scanning electron 388 
micrograph of control and IPF fibroblasts growing in their own extra cellular matrix (ECM). Vehicle 389 
treated preparations show cross linking ECM strands and webs. Inhibition of transglutaminases with 390 
cystamine or the LOX family with β-amino-proprionitrile (βAPN) results in highly disordered ECM with 391 
loss of the fibrillary structures. (b) Inhibition of transglutaminases or the LOX family during ECM 392 
deposition significantly inhibits fibroblast adhesion on IPF derived but not control ECM (n=3) (c) 393 
Inhibition of transglutaminases or the LOX family during ECM deposition significantly inhibits 394 
fibroblast growth over 48 hours as assessed by MTT assay. (d) In vitro collagen / fibronectin cross-395 
linking by recombinant TG2 significantly enhances control fibroblast adhesion over non cross-linked, 396 
vehicle treated collagen / fibronectin. The enhanced adhesion is inhibited by cystamine (cys) (n=3). (e) 397 
In vitro collagen / fibronectin TG2 cross-linking enhances increases control cell fibroblast number 398 
the presence of 1% FBS compared with vehicle treated collagen / fibronectin (n=3). * P<0.05, ** 399 
P<0.01. 400 
 401 
Figure 6. Tritiated hydroxyproline release from IPF ECM is due to endogenous proteases. Liberation 402 
of radio-labelled collagen fragments from EMC derived from IPF fibroblasts treated with either 403 
cystamine or vehicle, normalised to scintillant only background. Cystamine treatment of IPF ECM 404 
enhances spontaneous ECM turnover which is reduced by a broad spectrum protease inhibitor 405 
(protease i) but is not further increased by active MMP-1. * P<0.05. 406 
 407 
Figure 7. Cystamine inhibits transglutaminase activity and reduces fibrosis in vivo. (a) Bleomycin (bleo) 408 
treatment of ex vivo lung tissue significantly increases transglutaminase activity which is inhibited by 409 
cystamine (cys, P<0.05, n=3). AU=arbitrary unit of relative transglutaminase activity. (b) Treatment of 410 
animals with cystamine from days 24 to 34 post bleomycin instillation reduces total lung hydroxyproline. 411 
** P <0.01, * P <0.05. 412 
 413 
  414 
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ECM crosslinking enhances fibroblast growth and protects against matrix proteolysis in lung fibrosis. 
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Supplementary Methods 
 
Primary cell isolation and culture 
IPF fibroblasts are obtained from surplus lung parenchymal tissue from patients undergoing lung 
resections for the diagnosis of interstitial lung disease. Control fibroblasts are obtained from otherwise 
normal tissue distant from lung cancer resections. All patients had a pathological diagnosis of usual 
interstitial pneumonia and a clinical diagnosis of IPF. Tissue collection is approved through the 
Nottingham University Hospitals biobank and all patients give written, informed consent. Tissue was 
dissected into small 3mm cubes and placed in T25 culture flasks. DMEM + 10% FCS, 4mM L-glutamine, 
200U/ml penicillin, 200ug/ml streptomycin and 5ug/ml amphotericin B was added and fibroblasts 
grown out. At passage 2, media was changed and all antibiotic and antimycotic agent concentrations 
halved. At passage 3, all antibiotic and antimycotic agents were withdrawn, resulting in fibroblasts in 
DMEM + 10% FCS. Cells are characterised morphologically and by immunostaining for fibroblast 
specific protein, fibroblast activation protein and smooth muscle actin. Cells are used at passages 2-5. 
Airway smooth muscle cells extracted from large airways of patients who had died due to non-
respiratory causes were used for comparison purposes and have been described previously 1. 
 
Immunofluorescence  
Cells were grown in chamber slides, fixed with formaldehyde, permeabilised using 0.15% Triton X-100, 
blocked with 10% Goat Serum overnight at 4 °C.  Antibodies were incubated at 1:250, at room 
temperature for 1 hour, washed and incubated using a secondary flourophore conjugated antibody, 
washed then further incubated with CY-3 directly conjugated anti α-SMA (Sigma Aldrich, UK). In the 
final wash, DAPI (Sigma Aldrich, UK) was added to the PBS at 1:1000. Slides were removed and 
mounted using Dako Fluorescent Mounting Medium (Dako, Glostrup, Denmark). Slides were imaged 
using an Improvision spinning disc confocal microscope using Volocity 3D image analysis software 
(Perkin Elmer, Massachusetts, USA). 
 
Total RNA Extraction 
Total RNA was extracted from cultures at approximately 80% confluence in 6 well plates (~1x106 cells) 
using the GenElute™ Mammalian Total RNA Miniprep Kit (Sigma Aldrich, Dorset, UK). On-Column 
DNase I Digestion Set (Sigma Aldrich, Dorset, UK) was used during RNA extraction to remove genomic 
DNA contamination and prevent false positive PCR traces. RNA was eluted in 30µl of the elute solution 
and analysed on a NanoDrop (Fisher Scientific, UK) for quantity and quality. 
 cDNA Synthesis 
cDNA was synthesised using Superscript First-Strand Synthesis System (Invitrogen, UK) to the 
manufacturers specifications. 
 
Real Time PCR 
Quantitative RT-PCR was conducted to assess the relative abundance of gene transcripts. SensiFAST 
SYBR No-ROX Master Mix (Bioline Reagents Ltd., UK) was used as master mix when plating out PCR 
reactions. Reactions were run using the Mx3005P qPCR System with MxPro Software (Agilent 
Technologies, CA, USA). Predesigned KiCqStart SYBR Green primers were obtained from Sigma Aldrich 
(Dorset, UK). PCR data was analysed using the 2-δct method (Livak and Schmittgen, 2001, Rao et al., 
2013) which provides normalisation to an endogenous reference in differing cDNA added to the 
reaction mixture. As total copy number is not a goal of these experiments, relative quantification is 
suitable as no standard curve is needed. Internal controls were validated to show that there was little 
variation of housekeeping gene expression with experimental protocols.  
  
Data Analysis, Statistics and Graphical Software 
Unless otherwise stated, all data were processed using Microsoft Excel 2010 (Microsoft, USA) and 
graphed and analysed using Prism V6 (GraphPad Software, USA). Unless otherwise stated, n=3 
experimental data are presented with ± standard deviation (SD). Statistics were performed on data 
using Prism V6 (GraphPad Software, USA). 
 
Immunohistochemistry 
Paraffin embedded tissue was deparaffinised using Histoclear (National Diagnostics) and rehydrated 
in a graded alcohol series. Antigen retrieval was performed using a low pH citrate based antigen 
unmasking solution in a steamer. Endogenous peroxidases were quenched using 3% hydrogen 
peroxide and blocked with 2.5% Normal Horse Serum (Vector Laboratories). Antibodies were diluted 
in blocking agent. Both Impress Anti-Mouse and Impress Anti-Rabbit secondary antibody kits were 
obtained from Vector laboratories and performed to their manufactures specifications. Colour was 
developed using DAB Peroxidase (HRP) Substrate Kit (Vector Laboratories) and counterstained with 
Haematoxylin. Slides were mounted with a glass cover slip and Vectamount permanent mounting 
medium (Vector Laboratories, CA, USA). 
 
MTT Assay 
1x106 fibroblasts were seeded onto each ECM preparation and incubated with either serum free 
DMEM, DMEM+1% FCS, DMEM+5ng/ml PDGF-bb or 20ng/ml PDGF-bb for 72 hours then incubated 
with 0.5mg/ml Thiazolyl Blue Tetrazolium Bromide (Sigma Aldrich) in DMEM/F12 phenol red free 
media (Life Technologies) for 6 hours, 1ml of isopropanol added to and colour read in triplicates in a 
96 well plate and the absorbance read at 595nm, with background subtraction at 690nm, in the 
Flexstation 3 (Molecular Devices, CA, USA). 
 
Adhesion Assay  
Control fibroblasts were incubated with CellTracker Green CMFDA Dye (Life Technologies, UK) at 5µM 
final concentration in DMEM+10%FBS for 30 minutes. Cells were trypsinised, resuspended in serum 
free DMEM, seeded onto the ECM preparations and incubated for 2 hours at 37°C. Media and non-
adherent cells were aspirated, the plate washed with PBS and average fluorescence of each sample at 
Abs. 492 / Em. 517nm using flexstation 3 (Molecular Devices, CA, USA).  
 
Apoptosis assays 
Following overnight incubation on  3 IPF and 3 control derived ECM preparations, control fibroblast 
apoptosis was induced by 1µM Staurosporine or 100ng/ml Fas ligand in serum free DMEM for 24 
hours. Samples were then lysed in RIPA buffer for western blot analysis of Caspase 3 activation and 
PARP cleavage. DNA fragmentation was also determined using the In Situ Cell Death Detection Kit 
(fluorescin) (Roche Diagnostics Ltd., UK) and counter stained with DAPI for total nuclei counts. 
Fluorescein-dUTP positive cells were identified by confocal microscopy and expressed as a 
percentage of the total cells in a fixed field of view using three fields per sample.  
 
DNA Synthesis Assay 
To determine the number of proliferating cells through an independent method, a DNA synthesis 
approach was taken. Cells were cultured in the same way as described above for the MTT assay.  To 
directly measure new DNA synthesis the Click-iT® EdU Microplate Assay was used (Life Technologies) 
to manufacturers specifications with a final concentration of 10µM EdU and incubation time of 24 
hours. The 96 well plate was read with excitation/emission of 568/585nm using the Flexstation 3 
(Molecular Devices). 
 
ECM preparation and quantification  
Cultures were grown in DMEM+10% FBS to confluence and for a further 3 days to ensure sufficient 
matrix deposition. Culture media was aspirated and frozen at -20°C for later analysis. Cultures were 
washed with Phosphate Buffered Saline (PBS). Decellularization was adapted from a previously 
described method2. Cultures were incubated at room temperature with 50mM NH4OH + 0.05% 
Triton X-100 (Sigma Aldrich, Dorset, UK) in PBS for 15 minutes or until cells were no longer visible 
under 10x magnification on a Nikon Diaphot 300 Inverted Microscope (Nikon UK Limited, UK). 
Ammonium hydroxide and triton solution was aspirated and the cultures briefly washed with 50mM 
NH4OH. Following this, all plates were washed 3 times with PBS. Upon completion, all liquid was 
aspirated and all dishes were incubated at 37°C with 20 U/mL DNase I (Sigma Aldrich, Dorset, UK) to 
remove DNA contamination for 1 hour then washed 3 times with PBS before further 
experimentation. This resulted in a cell free and intact ECM as confirmed by SEM.  
A two stage extraction process was used as described by Ngoka3 with the following modifications. RIPA 
buffer and Complete Mini Protease Inhibitor Cocktail + EDTA was added to ECM preparations and 
incubated at room temperature for 5 minutes on a platform rocker and aspirated. Urea Lysis Buffer 
(PBS, pH 7.4, 5.0 M Urea, 2.0 M Thiourea, 50 mM DTT, 0.1% SDS) was then applied for 5 minutes at 
room temperature on a platform rocker. ECM extracts were dialysed using Slide-A-Lyzer G2 0.5mL/2K 
MWCO cassettes (Thermo Fisher Scientific Inc., USA) and stored at -20°C. 
Total protein assays were performed using a Bio-Rad Total Protein Assay Kit according to the 
manufactures specifications. To measure total collagen, ECM samples were subjected to acid 
hydrolysis. Solubilised ECM is diluted 1:1 with 12M HCl, incubated for 20 hours at 95 °C, centrifuged for 
10 minutes at 13,000xg and supernatants assayed using the Total Collagen Assay Kit (Quickzyme 
Biosciences, NL) according to the manufacturer’s specification. 
Collagen synthesis assay medium was supplemented with tritiated proline to a final activity of 1 µCi/ml 
(Perkin Elmer, MA, USA), decellularized as described. Solubilised samples were transferred to 
scintillation vials containing 10mls of Ultima Gold XR Scintillation fluid (Perkin Elmer) was added to 
each vial and the radioactivity read on a LKB Wallac 1214 Rackbeta Liquid Scintillation Counter (Perkin 
Elmer, USA). 
 
Generation of transglutaminase 2 ECM crosslinking in vitro  
Cross-linked collagen/fibronectin substrates were generated by incubating 50ug/ml collagen type 1 
(Advanced Biomatrix, USA) with 50ug/ml fibronectin (Sigma Aldrich, UK) diluted in serum free DMEM 
(Sigma Aldrich, UK) in the presence of recombinant TG2 to a final concentration of 500ng/ml. Control 
collagen/fibronectin mixtures were incubated with either PBS vehicle control, or TG2 (500ng/ml) pre-
incubated with the TG2 inhibitor cystamine (0.5mM) for 15 minutes at 37°C. Mixtures were incubated 
overnight in a shaking incubator at 37°C in six well plates. Prior to seeding, any remaining solution was 
aspirated, substrates washed in PBS and fibroblasts seeded at 150,000 cells per well in DMEM + 1% 
FBS. Adhesion and proliferation were assessed as previously described. 
 
ECM Proteolysis Assay 
1×106 cells/well are plated in 6 well plates and media was supplemented with L-[2,3,4,5-3H]-Proline 
to a final activity of 1 µCi/ml (Perkin Elmer, MA, USA) during matrix synthesis. Matrix labelling was 
confirmed by matrix extraction and liquid scintillation counting. After 72 h media are removed, 
plates washed with PBS and cells removed as described above. The soluble ECM fraction is collected 
and protein concentration determined using the BCA assay. Dishes are washed with PBS and the 
remaining ECM degraded using 1 μg/ml recombinant MMP (Biogenesis, Poole, UK) in reaction buffer 
(0.5 M Tris–HCl, 1.5 M NaCl, 50mM CaCl2 pH7.6). MMPs are activated by the addition of 2mM 
aminophenylmercuric acid (APMA) at 37°C prior to use. Serum free DMEM and APMA was used as a 
vehicle control, and serum free DMEM with Complete Mini Protease Inhibitor (Roche) as a negative 
control. Proteolysis was quantified by scintillation counting of supernatants. Fifty µls of the 
supernatant are removed and digested ECM determined by scintillation counting. The remaining 
ECM is solubilised and degradation expressed as % degradation of the total 3H proline labelled ECM. 
 
Culture of fibroblasts on ECM substrates of variable stiffness 
Tissue culture plates containing silicone gels of Young’s modulus of 0.2kPa, 0.5kPa, 2kPa, 8kPa, 16kPa, 
32kPa and 64kPa (SoftSubstrates, CA, USA) were used to assess the effect of ECM stiffness on TG2 
activity. Six well plates of variable stiffness were coated in 100ug/ml collagen (Advanced Biomatrix, 
USA) overnight at room temperature. Remaining collagen solution was aspirated and cells seeded at 
300,000 cells per well in serum free DMEM.  
 
Scanning Electron Microscopy  
Cell cultures were grown on glass cover slips and decellularised or imaged directly. Cultures were 
washed with PBS and replaced with a 3% glutaraldehyde overnight at room temperature. After 
washing 1% Osmium Tetroxide was added for 2 hours, washed and dehydrated in ethanol. Critical 
point drying using liquid CO2 to remove any remaining moisture and they were gold coated using a 
sputter coater before being transferred back for imaging. Samples were imaged on a JEOL 6060LV 
variable pressure scanning electron microscope (Jeol Ltd, UK). 
 
Transglutaminase Activity Assay 
Transglutaminase activity was determined using the Transglutaminase Assay Kit (Sigma Aldrich) 
according to the manufacturers instructions.  
 
TG2 and LOXL3 protein quantification 
Human TG2 and LOXL3 ELISAs were obtained from Cloud Clone Corps. (USA) and Cusabio. Life 
Science (China) respectively and performed according to the manufacturer’s protocols. 
 
LOX Activity Assay 
LOX activity was measured using a fluorometric assay obtained from Abcam (UK) and performed to 
the manufacterer’s protocols with a final sample volume of 50µl supernatant. 
 
Quantification of histological staining 
Stain intensity and proliferation were analysed in 8 IPF biopsies to assess the potential correlation 
between the N-epsilon gamma glutamyl lysine cross-link and Ki67 positive proliferating cells. This 
was done in sequential sections in the same region of interest in each biopsy. The ‘Fiji’ version of 
ImageJ was used for this process4. In the cross link stained sections the images were colour 
deconvoluted using the H DAB vector with the preset RGB values. Of the three images each was split 
into, Image 2 was used for quantification. The mean grey value was taken for each Image 2 from all 
donors and converted to OD using the formula 𝑂𝐷 = log⁡(
𝑚𝑎𝑥𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
𝑚𝑒𝑎𝑛𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
). Proliferation was assessed 
by counting total cell number and all positive cells in each Ki67 stained section.  
 
Ethical statement for animal use 
All animal work was approved by the Animal Welfare and Ethical Review Board (AWERB) of the 
University of Nottingham (UK) and conducted in accordance with all terms of the Establishment, 
Project and Personal Licences issued by the Secretary of State for the Home Office. Consistent with 
all national and international law, studies were carried out as detailed in the Animal [Scientific 
Procedures] Act 1986 (Amended Regulations 2012) (ASPA), Animal Welfare Act 2006, Directive 
2010/63/EU, the LASA guidelines and in respect to the principals of Replacement, Reduction and 
Refinement. Work was performed under licence number RGJ 40/3709 using the 19b3 protocol.  
 
Animals and Husbandry 
Power calculations were performed using PS version 3.1.25. Previous work from the Jenkins group 
(University of Nottingham, UK) was used to calculate the values for α at 0.001, δ at 500, σ at 200 
with a power of 0.95. This yielded a sample size of 8 for animal work with a standard deviation 
assumed of 200µg hydroxyproline and the difference of the group means of 500µg hydroxyproline. 
This enables us to study 8 pairs of subjects to be able to reject the null hypothesis that this response 
difference is zero with probability (power) 0.95. The Type I error probability associated with this test 
of this null hypothesis is 0.001. 
C57BL/6 Mice were obtained from Charles River Laboratories (Wilmington, Mass. USA.) at age 6 – 8 
weeks old. Animals were housed in a Specific Pathogen Free (SPF) environment in the Bio Support 
Unit, University of Nottingham, UK. Mice were randomly divided into a maximum of 4 mice per cage. 
Cages used were Techniplast GR500 Individually Vented Cages (IVC) at 21˚C and 50% humidity with 
environmental enrichment. Bedding consisted of Nestpak grade 5 sawdust (Datesand Ltd., UK) and 
Sizzle-Nest (Scanbur, Denmark). Mice were fed ad libitum 2018S Teklad Global 18% Protein Rodent 
Diet (Harlan Laboratories, UK) with constant access to fresh, filtered water and maintained on a 12 
hour light, 12 hour dark cycle. Food and bedding was sterilised by autoclaving prior to use. Following 
receipt of the animals, they were left in their new environment for 5 days to acclimatise before any 
experimental work began.  
Ex Vivo TG2 activity in Bleomycin injured tissue 
Lung was harvested from three 8 week old C57BL/6 mice and dissected into 3mm cubes. Tissue 
cubes were placed into 6 well plates in serum free DMEM overnight. The following morning media 
was aspirated and media containing DMEM + 1% Insulin-Transferrin-Selenium (Gibco) + 100U/ml 
penicillin + 0.1mg/ml streptomycin (Sigma Aldrich, Dorset, UK). Bleomycin was added to non-control 
samples at 5ug/ml on the lung samples and 15ug/ml on liver samples. This was chosen as liver 
samples were approximately three times heavier per cube than lung tissue cystamine was added to 
a final concentration of 0.5mM to one of the non-Bleomycin treated samples and to one of the 
Bleomycin treated. Samples were incubated in humidified atmosphere with 5% CO2 at 37°C for 23 
hours. Cystamine was added to a further tissue sample at t+23 hours. Incubation was resumed for 
another hour before all media was harvested for assay. Transglutaminase activity was assayed 
immediately following harvest. Data were normalised per mg of tissue. 
 
Bleomycin Model of Fibrosis 
All mice were anaesthetised with 2.5% inhaled isoflurane in a stream of oxygen (AB-G), weighed and 
ear marked. All mice received a single oropharyngeal administration of 60 IU Bleomycin (2mg/kg) in 
50ul 0.9% sterile PBS or PBS only. All mice were closely monitored for full recovery and checked for 
health and weight loss exceeding 25% of starting weight once daily for 7 days and thereafter as 
required but minimum twice weekly. Day 0-14, during the inflammation stage, mice were observed 
for any deterioration in health before administration of experimental cystamine. 
 
Murine Experimental Procedures 
Mice were randomly allocated to each treatment group. Following bleomycin installation mice 
received intraperitoneal (IP) injection of 100µl saline or cystamine once daily for 10 consecutive days 
during time course (TC) 1 and 11 for TC 2, starting at various time points (TP), precisely d14, d24 and 
d34. The day after the last IP, mice were sacrificed by terminal anaesthesia (AC) as described below. 
The dose of cystamine was calculated based on an average weight of bleomycin treated mice at the 
starting point of each IP treatment series.  
 
Terminal Anaesthesia and sample collection 
Sacrifice was conducted in accordance with ASPA Schedule 1. Avertin, or tribromoethanol, is no 
longer sold commercially for anaesthesia, therefore a non-pharmaceutical alternative was made 
under guidance of the Named Veterinary Surgeon (NVS). This was done by dissolving 5g 2,2,2-
tribromoethanol (Sigma-Aldrich) in 5ml 2-methyl-2-butanol (Sigma-Aldrich) under vigorous agitation 
in sterile conditions. This 100% Avertin solution was stored under light protection at 4˚C. Just prior 
to use, a working solution was made by diluting the stock solution to 2.5% using warmed PBS. pH 
was assessed in every batch before use. 
Terminal anaesthesia was carried out by administering 500µl of 2.5% Avertin by IP injection. This 
calculation is based on a 25g mouse and was adjusted accordingly per average cage weight. 
Induction required 1-2 minutes and mice were left for at least 5 minutes to enter deep anaesthesia 
and then checked by pinching the foot and for blink reflex. Tissue was collected, weighed, and snap 
frozen on dry ice for protein analysis.  
  
Supplementary Results 
 
Fibroblast characterisation 
Fibroblasts obtained from control and IPF lung resections were characterised by their adherence to 
plastic tissue culture plates, morphology and the expression of S100A4, FAP and αSMA. Commercial 
human lung fibroblasts had the same morphology and expressed the same markers as those derived 
from primary tissue (supplementary figure 1). Whilst airway smooth muscle cells expressed the same 
markers at a lower level they could be distinguished by the presence of well-developed actin stress 
fibers as previously described6. 
 
Characterisation of fibroblast derived ECM 
ECM derived from normal and IPF fibroblasts was imaged by electron microscopy and was observed 
to coat tissue culture surfaces evenly and be free of cellular debris (supplementary figure 2a). Total 
ECM protein was measured in soluble and insoluble fractions. There was no significant difference in 
either ECM protein fraction between normal and IPF derived fibroblasts (supplementary figure 2b). 
Total collagen, measured using a hydroxyproline assay, was predominantly located in the insoluble 
fraction but did not differ between normal and IPF derived fibroblasts (supplementary figure 2c). 
Labelling ECM by incubating fibroblasts during ECM deposition with tritiated proline confirmed that 
deposition of proline labelled ECM (predominantly collagen) was also equal in normal and IPF 
derived fibroblasts (supplementary figure 2d). 
 
Collagen 1-5 mRNA levels 
Quantitative RT-PCR was conducted to ascertain if the matrix varied in terms of relative collagen 
levels expressed by the cells rather than total quantity as shown by the hydroxyproline and tritiated 
proline incorporation assays. Cells were cultured as previously described to passage 4, RNA 
extraction, cDNA synthesised and RT-PCR was conducted with ribosomal 18S as the housekeeping 
gene using KiCqStart SYBR Green Primers for the alpha chains of collagens 1-5 (Sigma Aldrich, 
Dorset, UK). Collagen type III was the most highly expressed transcript, with Collagen II being the 
lowest expressed relative to 18s as shown. Collagen I in control cells was expressed at low levels 
relative to 18S and at similar levels between cells within the group. This is in contrast to the IPF 
group where the standard deviation is greater than that of control (supplementary figure 3). No 
statistical difference was observed between the IPF and control fibroblasts (n=3). 
 
IPF ECM does not protect against induced apoptosis  
To determine if IPF derived ECM could protect fibroblasts against apoptosis: control and IPF derived 
fibroblasts were treated with either Fas ligand (100ng/ml) or staurosporine (1µmol) for 24 hours to 
induce apoptosis whilst on control or IPF derived ECM. Levels of TUNEL staining ranged between 20 
to 30% in both control and IPF derived fibroblasts treated with either Fas ligand or staurosporine. 
Whilst IPF derived fibroblasts on fibroblast derived ECM tended to have lower levels of apoptosis, 
these differences, and all other combinations of cell type or matrix substrate, were not significant 
(supplementary figure 6). Similarly Caspase 3 and PARP cleavage assessed by western blotting under 
the same conditions did not differ between cell or matrix type. 
 
Figure Legends  
Supplementary figure 1. Characterisation of control and IPF derived fibroblasts. Images of 
stained primary human airway smooth muscle (ASM) cells (used as controls), IPF and control 
patient derived fibroblasts. All cells are stained with anti α-smooth muscle actin (α-SMA, 
red) and DAPI (blue). Green staining is used for anti-S100A4 and fibroblast activation protein 
(FAP-1) as indicated. Control and IPF derived fibroblasts have similar morphology and 
staining patterns. ASM cells express s100A4 and FAP at a lower level than fibroblasts and 
have more pronounced stress fibers. Representative images are shown. For each cell type 
three separate donors were studied. 
 
Supplementary figure 2. Characterisation of fibroblast derived ECM. (a) Fibroblast derived 
ECM preparation visualised by scanning electron microscopy showing a complex filamentous 
layer free from cells and debris. (b) Control and fibroblast ECM preparations analysed by BCA 
assay contain similar levels of total protein in their soluble and insoluble fractions. (c) 
Measurement of total collagen in ECM preparations show this is similar in control and IPF 
derived fibroblasts and largely in the insoluble fraction. (d) Equal collagen synthesis between 
control and IPF derived fibroblasts is confirmed by tritiated proline incorporation assay.  
 
Supplementary figure 3. Collagen Type I-V mRNA expression does not vary between IPF 
and control fibroblasts. (a-e) Collagen types I-V mRNA does not vary between IPF and 
control fibroblasts assayed by real time PCR. Data presented ±SD, n=3. 
 
Supplementary figure 4. Lysyl Oxidase like protein (LOXL) expression in IPF tissue. LOXL2 is 
expressed in control and IPF lung. LOXL3 is not present in control lung but weakly positive in 
IPF lung. Brown indicates positive staining; Blue indicates haematoxylin counterstaining of 
nuclei. Magnification x20. 
 
Supplementary figure 5. IPF derived ECM induces LOXL3 expression. Three control and 
three IPF derived fibroblasts were cultured on three control and three IPF derived ECM 
preparations and gene expression for cross linking enzymes quantified by real time PCR. 
LOXL3 was strongly induced on IPF derived ECM in both cell types. TG2 shows a trend 
towards increased expression in IPF derived fibroblasts regardless of matrix type. LOX shows 
a trend towards lower expression on IPF derived ECM however neither are significant. These 
data are bar graphs of the same data as shown in figure 3 in the main manuscript.  
 
Supplementary figure 6. IPF ECM does not protect against staurosporine or fas ligand 
induced apoptosis. Three control and three IPF derived fibroblasts were cultured on three 
control and three IPF derived ECM preparations and apoptosis induced by staurosporine 
(1μg) or fas ligand (100ng/ml) for 24 hours. (a & b) IPF matrix did not affect the percentage 
of TUNEL positive cells induced by either agent when compared with control ECM. (c) 
Western blotting of or three control and IPF derived fibroblasts cultured on control and IPF 
derived ECM and treated with staurosporine (1μg) or fas ligand (100ng/ml), shows no 
difference in cleaved PARP or caspase 3 between ECM types.  
 
Supplementary figure 7. Serum LOXL3 and transglutaminase 2 are not elevated in patients 
with IPF. (a & b) Serum LOXL3 and Transglutaminase 2 (c & d) are not elevated in serum 
from patients with IPF or related to survival at three years or lung function.  
 
Supplementary figure 8. ECM stiffness does not affect fibroblast transglutaminase activity. 
Control fibroblasts were cultured on ECM substrates with a Young’s modulus of 0.5 to 64 kPa 
and incubated for 24 to 72 hours. ECM stiffness had no impact upon fibroblast derived 
transglutaminase activity.  
 
 
 
Supplementary figure 9. Association of TG2 mediated cross-linking with proliferation. (a) 
Immunohistochemical staining of TG2 mediated cross-links and ki67 in fibrotic regions from 
eight IPF lung biopsies. Proliferating cells are identified by brown nuclear staining. (b) 
Quantification of TG2 staining and ki67 positive cells in eight IPF biopsies. Cell proliferation 
and TG2 cross-link density are not significantly related R
2
=0.011 
 
Supplementary figure 10. Tritiated hydroxyproline release from ECM during MMP 
mediated proteolysis. Liberation of radio-labelled collagen fragments from control and IPF 
derived IPF treated with vehicle, cystamine of βAPN, normalised to scintillant only 
background in the presence of: (a) DMEM only control (b) APMA vehicle control (c) APMA 
activated MMP-1 (d) MMP-2 (e) MMP-1 and -2 (f) MMP7. Data presented ±SD. DPM= 
disintegrations per minute. n=3. 
 
Supplementary figure 11. Total lung hydroxyproline in the bleomycin model over time. 
Mice were treated with intra-tracheal saline or bleomycin at day 0 and total lung 
hydroxyproline measured after 24, 34 and 44 days. Bleomycin was associated with increased 
whole lung collagen but this did not change significantly over the period of measurement. * 
P<0.05, ***P<0.001, n=4. 
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